Nutraplus India Ltd
Nutraplus India is engaged in the Business of Drugs and Pharmaceuticals.
- Market Cap ₹ 7.16 Cr.
- Current Price ₹ 2.10
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 17.0
- Dividend Yield 0.00 %
- ROCE 3.00 %
- ROE -2.97 %
- Face Value ₹ 5.00
Pros
- Stock is trading at 0.12 times its book value
Cons
- Company has low interest coverage ratio.
- Contingent liabilities of Rs.3.89 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2014 | Mar 2015 | TTM | |
---|---|---|---|---|
45 | 62 | 65 | 63 | |
38 | 51 | 62 | 59 | |
Operating Profit | 6 | 10 | 3 | 3 |
OPM % | 14% | 17% | 5% | 5% |
0 | 0 | -3 | -23 | |
Interest | 2 | 4 | 5 | 4 |
Depreciation | 1 | 2 | 1 | 1 |
Profit before tax | 4 | 5 | -6 | -25 |
Tax % | 31% | 39% | 28% | |
3 | 3 | -4 | -24 | |
EPS in Rs | 2.59 | 2.41 | -1.66 | -20.13 |
Dividend Payout % | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -111% |
Stock Price CAGR | |
---|---|
10 Years: | -10% |
5 Years: | -33% |
3 Years: | -4% |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2014 | Mar 2015 | |
---|---|---|---|
Equity Capital | 5 | 6 | 11 |
Reserves | 8 | 14 | 31 |
15 | 32 | 40 | |
16 | 23 | 32 | |
Total Liabilities | 44 | 75 | 114 |
19 | 36 | 23 | |
CWIP | 0 | 1 | 13 |
Investments | 2 | 0 | 4 |
23 | 39 | 74 | |
Total Assets | 44 | 75 | 114 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2014 | Mar 2015 | |
---|---|---|---|
4 | -16 | ||
-11 | -5 | ||
7 | 32 | ||
Net Cash Flow | 0 | 10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2014 | Mar 2015 | |
---|---|---|---|
Debtor Days | 98 | 88 | 75 |
Inventory Days | 82 | 170 | 134 |
Days Payable | 151 | 168 | 187 |
Cash Conversion Cycle | 30 | 89 | 22 |
Working Capital Days | 57 | 84 | 174 |
ROCE % | 3% |
Documents
Announcements
- Reg. 34 (1) Annual Report. 28 Feb
- Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015) 24 Dec 2020
- Proceeding Of 30Th Annual General Meeting Of The Company. 22 Dec 2020
- Reg. 34 (1) Annual Report 4 Dec 2020
- Outcome Of Board Meeting Held On November 16, 2020 17 Nov 2020
Annual reports
Concalls
-
Sep 2016TranscriptNotesPPT